MCL Literature Feed

The CDK9 inhibitor enitociclib overcomes resistance to both BTK inhibitors and CAR-T therapy, offering a potential new strategy for double-refractory mantle cell lymphoma.

The SOX11/PRDX2 axis is identified as a key regulator of chemoresistance in aggressive MCL by controlling redox homeostasis, offering a potential new therapeutic target.

In a retrospective analysis of 95 MCL cases, specific histopathological patterns of bone marrow involvement were identified as key prognostic indicators, aiding in initial patient risk stratification.

This case series characterizes the immunohistochemical and molecular genetic profile of rare lacrimal gland MCL, providing crucial diagnostic insights for this uncommon extranodal presentation.

An 85-year-old MCL patient on ibrutinib developed a cutaneous EBV+ NK/T-cell lymphoma that resolved spontaneously, highlighting a rare, potentially indolent lymphoproliferative disorder in this treatment setting.

PRMT5 promotes MCL growth via MYC-driven lipid metabolism reprogramming, identifying it as a poor prognostic marker and a novel therapeutic target with preclinical inhibitor activity.

Adding bortezomib to R-HAD chemotherapy for relapsed/refractory MCL significantly improved time to treatment failure (12 vs 2.6 months), providing a valuable option when BTK inhibitors are unavailable.

A rare case of primary adrenal mantle cell lymphoma presenting as a retroperitoneal mass mimicking paraganglioma highlights the critical need for histological diagnosis of atypical adrenal tumors.

The non-covalent BTK inhibitor pirtobrutinib demonstrates efficacy in mantle cell lymphoma patients who have progressed on prior covalent BTKi therapy, overcoming a common resistance mechanism.

A case of primary ocular adnexal MCL demonstrates its potential for rapid systemic progression, emphasizing the need for thorough initial staging and aggressive systemic therapy despite localized presentation.

A steroid-sparing regimen of doxycycline, cetirizine, and valacyclovir successfully managed exaggerated mosquito bite reactions in an indolent MCL patient, offering a novel approach for this rare cutaneous manifestation.

This UK real-world, intention-to-treat analysis of brexu-cel confirms high efficacy in infused patients but reveals a 30% attrition rate before infusion and significant non-relapse mortality from infection.

This case report demonstrates delayed Hepatitis B reactivation with acalabrutinib in relapsed MCL, underscoring the need for viral screening and prophylaxis with second-generation BTK inhibitors.

This retrospective study confirms that progression of disease within 24 months (POD24) after initial therapy is a strong negative prognostic marker for overall survival in MCL patients.

This case report describes a rare presentation of intestinal MCL causing ileocecal intussusception in an adult, highlighting a critical differential diagnosis for this acute abdominal condition requiring pathological confirmation.

This case report describes a rare presentation of primary MCL causing life-threatening laryngotracheal stenosis, highlighting the need to consider lymphoma in the differential diagnosis of acute airway obstruction.

This case report links MCL with Henoch-Schönlein purpura and IgA-nephritis, highlighting a rare paraneoplastic syndrome with specific dermatological and renal manifestations for clinicians to recognize.

In young, newly diagnosed MCL, first-line rituximab, bendamustine, and cytarabine (R-BAP) plus a BTK inhibitor improved complete response and PFS over standard R-CHOP/R-DHAP in a real-world setting.

This systematic analysis of MAIT cells across hematological malignancies provides foundational insights into the MCL immune microenvironment, potentially identifying novel biomarkers or immunotherapy targets.

This report describes two contrasting presentations of MCL with plasmacytic differentiation, highlighting the diagnostic challenge of this rare variant which can mimic plasma cell neoplasms, impacting management.

In young, newly diagnosed MCL patients, adding ibrutinib to chemoimmunotherapy improves failure-free survival, establishing a new standard and questioning the necessity of autologous stem cell transplant consolidation.

The phase 3 TRIANGLE trial established that adding ibrutinib to induction/maintenance allows omission of autologous transplant in young, fit MCL patients, providing a new frontline, transplant-free standard.

This case report describes the rare phenomenon of biclonal mantle cell lymphoma, highlighting clonal heterogeneity and evolution which can impact diagnosis, disease progression, and therapeutic resistance.

This preclinical study identifies PLK-1 gene methylation as a key driver of bendamustine resistance, which was reversible with demethylating agents, suggesting a potential new therapeutic strategy.

This review summarizes the clinical data and rationale for targeted agents like BTK and BCL2 inhibitors, highlighting the paradigm shift away from chemotherapy in both relapsed/refractory and frontline MCL.

Transformed MCL with triple-hit genetics (MYC/BCL2/BCL6 rearrangements) can be resistant to BTK inhibitors, identifying a novel genomic mechanism of treatment failure in this aggressive setting.

Gene expression profiling identifies two distinct molecular MCL subtypes, C1 and C2, with C2 showing high proliferation and poor prognosis, providing a powerful new biomarker for risk stratification.

This preclinical study elucidates acalabrutinib's metabolic pathways, identifying reactive intermediates that may explain potential drug-drug interactions, toxicities, or off-target effects in patients with MCL.

This review details the evolution of BTK inhibitors, highlighting improved toxicity with newer agents and the emergence of non-covalent BTKis and novel resistance mutations, impacting MCL treatment sequencing.

This case links progressive necrotizing xanthogranuloma, a rare paraneoplastic syndrome, as the presenting sign of MCL, underscoring the need for hematologic workup for specific skin/ocular findings.